Report Detail
Global and Japan CAR-T Therapy in Haematological Malignancy Market 2020 by Company, Type and Application, Forecast to 2025
- RnM3961568 |
- 08 May, 2020 |
- Global |
- 96 Pages |
- GIR (Global Info Research) |
- Other
Market Overview
The CAR-T Therapy in Haematological Malignancy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The most likely (base case) scenario is that the global CAR-T Therapy in Haematological Malignancy sales will be xx in 2020 from CAR-T Therapy in Haematological Malignancy million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global CAR-T Therapy in Haematological Malignancy market size is expected to grow at xx% or more annually for the next five years.
This report also researches and evaluates the impact of Covid-19 outbreak on the CAR-T Therapy in Haematological Malignancy industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on CAR-T Therapy in Haematological Malignancy and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).
Market segmentation
CAR-T Therapy in Haematological Malignancy market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for revenue by Type and Application. This analysis can help you expand your business by targeting qualified niche markets.
Breakdown by Type, CAR-T Therapy in Haematological Malignancy market has been segmented into Allogeneic, Autologous, etc.
Breakdown by Application, CAR-T Therapy in Haematological Malignancy has been segmented into Hospitals, Cancer Research Centers, Others, etc.
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global CAR-T Therapy in Haematological Malignancy market presented in the report. This section sheds light on the sales growth of different regional and country-level CAR-T Therapy in Haematological Malignancy markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global CAR-T Therapy in Haematological Malignancy market.
For Japan, this report analyses the Japan market by players, Type and Application, for the period 2015-2025.
Competitive Landscape and CAR-T Therapy in Haematological Malignancy Market Share Analysis
CAR-T Therapy in Haematological Malignancy competitive landscape provides details by vendors, including company overview, company total revenue, market potential, global presence, CAR-T Therapy in Haematological Malignancy revenue generated, market share, headquarters, SWOT analysis, product launch. For the period 2015-2020, this study provides the CAR-T Therapy in Haematological Malignancy revenue and market share for each player covered in this report.
The major players covered in CAR-T Therapy in Haematological Malignancy are: Celgene (Juno Therapeutics), Sorrento Therapeutics, Pfizer, Novartis, Aurora BioPharma, Gilead (Kite Pharma), Bluebird Bio, Autolus Therapeutics, CARsgen Therapeutics, Mustang Bio, Collectis, Allogene Therapeutics, Celyad, etc. Among other players domestic and global, CAR-T Therapy in Haematological Malignancy market share data is available for global, North America, Europe, Asia, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Market segment by players, this report covers
Celgene (Juno Therapeutics)
Sorrento Therapeutics
Pfizer
Novartis
Aurora BioPharma
Gilead (Kite Pharma)
Bluebird Bio
Autolus Therapeutics
CARsgen Therapeutics
Mustang Bio
Collectis
Allogene Therapeutics
Celyad
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina)
MENA (Saudi Arabia, UAE, Turkey and South Africa)
Market segment by Type, covers:
Allogeneic
Autologous
Market segment by Application, can be divided into
Hospitals
Cancer Research Centers
Others
1 Market Overview
- 1.1 Product Overview and Scope of CAR-T Therapy in Haematological Malignancy
- 1.2 Classification of CAR-T Therapy in Haematological Malignancy by Type
- 1.2.1 Overview: Global CAR-T Therapy in Haematological Malignancy Revenue by Type: 2015 Versus 2019 Versus 2025
- 1.2.2 Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Type in 2019
- 1.2.3 Allogeneic
- 1.2.4 Autologous
- 1.3 Global CAR-T Therapy in Haematological Malignancy Market by Application
- 1.3.1 Overview: Global CAR-T Therapy in Haematological Malignancy Revenue by Application: 2015 Versus 2019 Versus 2025
- 1.3.2 Hospitals
- 1.3.3 Cancer Research Centers
- 1.3.4 Others
- 1.4 Global CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
- 1.5 Global CAR-T Therapy in Haematological Malignancy Market Size by Regions: 2015 VS 2019 VS 2025
- 1.6 Global CAR-T Therapy in Haematological Malignancy Market Size by Regions (2015-2020)
- 1.7 Global CAR-T Therapy in Haematological Malignancy Market Size and Forecast by Regions (2020-2025)
- 1.7.1 North America CAR-T Therapy in Haematological Malignancy Status and Prospect (2015-2025)
- 1.7.2 Europe CAR-T Therapy in Haematological Malignancy Status and Prospect (2015-2025)
- 1.7.3 Asia CAR-T Therapy in Haematological Malignancy Status and Prospect (2015-2025)
- 1.7.4 South America CAR-T Therapy in Haematological Malignancy Status and Prospect (2015-2025)
- 1.7.5 Middle East & Africa CAR-T Therapy in Haematological Malignancy Status and Prospect (2015-2025)
- 1.8 COVID-19 Outbreak: CAR-T Therapy in Haematological Malignancy Industry Impact
- 1.8.1 COVID-19 Potential Implications for the CAR-T Therapy in Haematological Malignancy
- 1.8.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on CAR-T Therapy in Haematological Malignancy
- 1.8.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
- 1.8.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
- 1.8.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
- 1.8.2 Opportunity Analysis in Covid-19 Crisis
- 1.8.3 Market Risk and Restraints
- 1.8.4 Market Driving Force
- 1.8.1 COVID-19 Potential Implications for the CAR-T Therapy in Haematological Malignancy
2 Company Profiles
- 2.1 Celgene (Juno Therapeutics)
- 2.1.1 Celgene (Juno Therapeutics) Details
- 2.1.2 Celgene (Juno Therapeutics) Major Business and Total Revenue (Financial Highlights) Analysis
- 2.1.3 Celgene (Juno Therapeutics) SWOT Analysis
- 2.1.4 Celgene (Juno Therapeutics) Product and Services
- 2.1.5 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
- 2.2 Sorrento Therapeutics
- 2.2.1 Sorrento Therapeutics Details
- 2.2.2 Sorrento Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
- 2.2.3 Sorrento Therapeutics SWOT Analysis
- 2.2.4 Sorrento Therapeutics Product and Services
- 2.2.5 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
- 2.3 Pfizer
- 2.3.1 Pfizer Details
- 2.3.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
- 2.3.3 Pfizer SWOT Analysis
- 2.3.4 Pfizer Product and Services
- 2.3.5 Pfizer CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
- 2.4 Novartis
- 2.4.1 Novartis Details
- 2.4.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
- 2.4.3 Novartis SWOT Analysis
- 2.4.4 Novartis Product and Services
- 2.4.5 Novartis CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
- 2.5 Aurora BioPharma
- 2.5.1 Aurora BioPharma Details
- 2.5.2 Aurora BioPharma Major Business and Total Revenue (Financial Highlights) Analysis
- 2.5.3 Aurora BioPharma SWOT Analysis
- 2.5.4 Aurora BioPharma Product and Services
- 2.5.5 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
- 2.6 Gilead (Kite Pharma)
- 2.6.1 Gilead (Kite Pharma) Details
- 2.6.2 Gilead (Kite Pharma) Major Business and Total Revenue (Financial Highlights) Analysis
- 2.6.3 Gilead (Kite Pharma) Product and Services
- 2.6.4 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
- 2.7 Bluebird Bio
- 2.7.1 Bluebird Bio Details
- 2.7.2 Bluebird Bio Major Business and Total Revenue (Financial Highlights) Analysis
- 2.7.3 Bluebird Bio Product and Services
- 2.7.4 Bluebird Bio CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
- 2.8 Autolus Therapeutics
- 2.8.1 Autolus Therapeutics Details
- 2.8.2 Autolus Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
- 2.8.3 Autolus Therapeutics Product and Services
- 2.8.4 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
- 2.9 CARsgen Therapeutics
- 2.9.1 CARsgen Therapeutics Details
- 2.9.2 CARsgen Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
- 2.9.3 CARsgen Therapeutics Product and Services
- 2.9.4 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
- 2.10 Mustang Bio
- 2.10.1 Mustang Bio Details
- 2.10.2 Mustang Bio Major Business and Total Revenue (Financial Highlights) Analysis
- 2.10.3 Mustang Bio Product and Services
- 2.10.4 Mustang Bio CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
- 2.11 Collectis
- 2.11.1 Collectis Details
- 2.11.2 Collectis Major Business and Total Revenue (Financial Highlights) Analysis
- 2.11.3 Collectis Product and Services
- 2.11.4 Collectis CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
- 2.12 Allogene Therapeutics
- 2.12.1 Allogene Therapeutics Details
- 2.12.2 Allogene Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
- 2.12.3 Allogene Therapeutics Product and Services
- 2.12.4 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
- 2.13 Celyad
- 2.13.1 Celyad Details
- 2.13.2 Celyad Major Business and Total Revenue (Financial Highlights) Analysis
- 2.13.3 Celyad Product and Services
- 2.13.4 Celyad CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
- 3.1 Global CAR-T Therapy in Haematological Malignancy Market Size by Players (2015-2020)
- 3.2 Japan CAR-T Therapy in Haematological Malignancy Market Size by Players (2015-2020)
- 3.3 Market Concentration Rate
- 3.3.1 Top 5 CAR-T Therapy in Haematological Malignancy Players Market Share
- 3.3.2 Top 10 CAR-T Therapy in Haematological Malignancy Players Market Share
4 North America Market Size and Forecast by Countries
- 4.1 North America CAR-T Therapy in Haematological Malignancy Market Size by Countries (2015-2020)
- 4.2 North America CAR-T Therapy in Haematological Malignancy Market Size and Forecast by Countries (2015-2026)
- 4.3 United States CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
- 4.4 Canada CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
- 4.5 Mexico CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
5 Europe Market Size and Forecast by Countries
- 5.1 Europe CAR-T Therapy in Haematological Malignancy Market Size by Countries (2015-2020)
- 5.2 Europe CAR-T Therapy in Haematological Malignancy Market Size and Forecast by Countries (2015-2026)
- 5.3 Germany CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
- 5.4 France CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
- 5.5 UK CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
- 5.6 Russia CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
- 5.7 Italy CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
6 Asia-Pacific Market Size and Forecast by Countries
- 6.1 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size by Regions (2015-2020)
- 6.2 Asia-Pacific CAR-T Therapy in Haematological Malignancy Market Size and Forecast by Regions (2015-2026)
- 6.3 China CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
- 6.4 Japan CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
- 6.5 Korea CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
- 6.6 India CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
- 6.7 Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
7 South America Market Size and Forecast by Countries
- 7.1 South America CAR-T Therapy in Haematological Malignancy Market Size by Countries (2015-2020)
- 7.2 South America CAR-T Therapy in Haematological Malignancy Market Size and Forecast by Countries (2015-2026)
- 7.3 Brazil CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
- 7.4 Argentina CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
8 Middle East & Africa Market Size and Forecast by Countries
- 8.1 Middle East & Africa CAR-T Therapy in Haematological Malignancy Revenue by Regions (2015-2020)
- 8.2 Middle East & Africa CAR-T Therapy in Haematological Malignancy Market Size and Forecast by Countries (2015-2026)
- 8.3 Saudi Arabia CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
- 8.4 UAE CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
- 8.5 Egypt CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
- 8.6 South Africa CAR-T Therapy in Haematological Malignancy Market Size and Forecast (2015-2025)
9 Market Size Segment by Type
- 9.1 Global CAR-T Therapy in Haematological Malignancy Market Size and Forecast by Type (2015-2025)
- 9.1.1 Global CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)
- 9.1.2 Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Type (2020-2025)
- 9.2 Japan CAR-T Therapy in Haematological Malignancy Market Size and Forecast by Type (2015-2025)
- 9.2.1 Japan CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)
- 9.2.2 Japan CAR-T Therapy in Haematological Malignancy Market Size Forecast by Type (2020-2025)
10 Market Size Segment by Application
- 10.1 Global CAR-T Therapy in Haematological Malignancy Market Size and Forecast by Application (2015-2025)
- 10.1.1 Global CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)
- 10.1.2 Global CAR-T Therapy in Haematological Malignancy Market Size Forecast by Application (2020-2025)
- 10.2 Japan CAR-T Therapy in Haematological Malignancy Market Size and Forecast by Application (2015-2025)
- 10.2.1 Japan CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)
- 10.2.2 Japan CAR-T Therapy in Haematological Malignancy Market Size Forecast by Application (2020-2025)
11 Research Findings and Conclusion
12 Appendix
- 12.1 Methodology
- 12.2 Data Source
- 12.3 Disclaimer
Summary:
Get latest Market Research Reports on CAR-T Therapy in Haematological Malignancy. Industry analysis & Market Report on CAR-T Therapy in Haematological Malignancy is a syndicated market report, published as Global and Japan CAR-T Therapy in Haematological Malignancy Market 2020 by Company, Type and Application, Forecast to 2025. It is complete Research Study and Industry Analysis of CAR-T Therapy in Haematological Malignancy market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
